Abstract: The present disclosure relates in some aspects to chimeric signaling receptors containing an extracellular domain capable of binding a molecule, such as an immunosuppressive cytokine, and a MyD88-containing intracellular domain capable of engaging a signaling pathway to activate an immune cell. In some aspects, the disclosure further relates to engineered cells, such as T cells, and compositions comprising the chimeric signaling receptors or engineered cells, and methods and uses thereof. In some embodiments, the cells may further express a genetically engineered recombinant antigen receptor directed against an antigen, such as a chimeric antigen receptor (CAR) or recombinant T cell receptor (TCR) and, in some cases, secrete a recombinant molecule, for example, a bispecific antibody.

Abstract: Described herein are methods for determining the subgroup of medulloblastoma in a subject in need thereof. The subgroups of medulloblastoma include Group 3, Group 4, WNT and SHH. The subjects are children diagnosed with medulloblastoma or children suspected of having medulloblastoma.

Abstract: The present invention provides for molecular analysis of gene expression of tumors at diagnosis as well as molecular analysis of tumor and normal cell gene expression in bone marrow and blood at diagnosis and during and after completion of treatment. These molecular analyses of gene expression provide an assessment of risk of recurrence and response to therapy of tumors, and in particular, neuroblastoma.